AA
CPRX

AlphaMark Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

AlphaMark Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,486
Closed -$328K – 641
2024
Q3 		$328K Buy
+16,486
New +$306K 0.11% 168
2019
Q3 		– Sell
-2,208
Closed -$8K – 488
2019
Q2 		$8K Buy
+2,208
New +$9.54K ﹤0.01% 357

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

AlphaMark Advisors's CPRX Position: Q4 2024 in Review

AlphaMark Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 16,486 shares — an estimated $328K sold.

AlphaMark Advisors first reported a position in CPRX in Q2 2019 and held it in 2 quarters. The position peaked at $328K in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • AlphaMark Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • AlphaMark Advisors sold 16,486 Catalyst Pharmaceutical shares in Q4 2024, an estimated $328K.
  • AlphaMark Advisors first reported a position in Catalyst Pharmaceutical in Q2 2019 and held it in 2 quarters.
  • AlphaMark Advisors's Catalyst Pharmaceutical position peaked at $328K in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.